Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation

Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor (PI) that has been shown in preclinical models to prevent GVHD. We conducted a phase I/II tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Chhabra, Saurabh, Visotcky, Alexis, Pasquini, Marcelo C., Zhu, Fenlu, Tang, Xiaoying, Zhang, Mei-Jie, Thompson, Robert, Abedin, Sameem, D’Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Rizzo, J. Douglas, Runaas, Lyndsey, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Horowitz, Mary M., Hari, Parameswaran N., Hamadani, Mehdi
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571859/
https://ncbi.nlm.nih.gov/pubmed/32653622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados